



Bruce E. Sands, MD, MS


Icahn School of Medicine at Mount Sinai
New York, NY, United States

Bruce Sands is on the didactic faculty of the Graduate School of Biomedical Sciences and a professor of medicine at Icahn School of Medicine at Mount Sinai in New York, New York. He also holds various appointments at 5 hospitals within the Mount Sinai Health System in New York.

Dr Sands earned his medical degree at Boston University School of Medicine in Boston, Massachusetts, and his master of science in epidemiology at Harvard School of Public Health in Boston. He also completed the Mass General Physician Organization certificate program in physician leadership at Massachusetts General Hospital in Boston.

He is an elected member of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), has received recognition as being among the best physicians in his field (eg, Castle Connolly America's and New York's top doctors over the past 5 years; *New York Times Magazine's* "New York Super Doctors"), and is a Clarivate "highly cited researcher." He has also been on the editorial board of many peer-reviewed journals, including *Inflammatory Bowel Disease*, *Gastroenterology*, *Digestive Diseases and Sciences*, and *World Journal of Gastroenterology*.

Dr Sands is the author or co-author of more than 400 publications in scientific journals and book chapters and has presented his research nationally and internationally.



**David T. Rubin, MD, FACG, AGAF,
FACP, FASGE, FRCP (Edinburgh)**
University of Chicago Medicine
Chicago, IL, United States

David T. Rubin is the Joseph B. Kirsner Professor of Medicine; professor of pathology; chief of the Section of Gastroenterology, Hepatology & Nutrition; and director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine.

Dr Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine, where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is an associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center, and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the immediate past chair of the National Scientific Advisory Committee of the Crohn's & Colitis Foundation and chair of the International Organization for the Study of IBD.

Dr Rubin's research is focused on disease modification in IBD, including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. He has twice received the ACG's Governor's Award of Excellence in Clinical Research (2003 and 2013), and in 2020, Dr Rubin received the Sherman Prize for Excellence in Crohn's and Colitis. In 2023, he received both the UChicago Michael Reese Lectureship Award (for outstanding faculty who have developed novel teaching and clinical research that advances healthcare) and the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award.

Dr Rubin is currently a senior editor of the 12th edition of Sleisenger and Fordtran's *Gastrointestinal and Liver Disease*, and an author of over 500 articles on the management of IBD, including the 2025 ACG Guidelines for ulcerative colitis.



Parambir S. Dulai, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL, United States

Parambir S. Dulai is a physician-scientist with clinical expertise in inflammatory bowel disease (IBD) and research expertise in clinical trial methodology and design, biomarker discovery, and multi-omic multi-dimensional data integration to study immune-mediated inflammatory diseases.

Dr Dulai completed his internal medicine residency and chief residency at Dartmouth. He then went on to complete an NIH-sponsored T32 GI research fellowship, chief fellow year, and IBD clinical preceptorship year at the University of California, San Diego (UCSD). He joined the faculty at UCSD in 2018, and during his first year, he completed an IBD clinical trials fellowship with Robarts Clinical Trials (now Alimentiv) to study IBD-specific clinical trial design, methodology, and regulatory interactions.

He was awarded an American Gastroenterology Association (AGA) research scholar award in 2019. In 2022, he was recruited to Northwestern University to lead the GI Clinical Trials and Precision Medicine programs, as well as the expansion and integration of the IBD program system-wide across Northwestern Medicine. In 2022, he was awarded the Sherman Emerging Leader Prize for his excellence in patient care and medical research in IBD.

The Dulai lab focuses on novel clinical trial designs, biomarker discovery, and personalized medicine. As the director of GI Clinical Trials, Dr Dulai oversees a robust clinical trial program that spans both industry- and federally sponsored trials. He serves on several steering committees for phase 2/3 drug development programs in IBD, and is the principal investigator for an NIDDK-sponsored U01 clinical trial for hyperbaric oxygen therapy in acute severe ulcerative colitis. His research program has helped to define emerging endpoints for clinical trials in IBD with the development of novel patient-reported outcome measurement tools, endoscopic indices, and considerations for integration of biomarkers into clinical trial designs.